Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s DiseaseContributed by: Business WireLogoTagsResearchGeneral HealthProfessional ServicesGeneticsHealth InsurancePublic Relations/Investor RelationsClinical TrialsScienceBiotechnologyCommunicationsFinanceHealthOther SciencePrasinezumab
